OR WAIT 15 SECS
Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.
Baxter BioPharma Solutions and Novavax announced on Jan. 11, 2021 that they have entered into a sterile manufacturing agreement for Novavax’s COVID-19 vaccine candidate, NVX-CoV2373.
Under the terms of the agreement, Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany, facility to prepare the vaccine candidate for distribution in the United Kingdom and European markets, Baxter said in a company press release. NVX-CoV2373 is currently undergoing Phase III trials and has not yet been authorized or approved for use.
“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice-president, Baxter BioPharma Solutions, in the press release. “We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.”
“Our priority is to bring a safe, effective COVID-19 vaccine to people around the world,” added Rick Crowley, executive vice-president, chief operations officer, Novavax, in the press release. “Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID-19 pandemic.”